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Abstract 
 
Introduction 
Several peripheral T-cell lymphomas (PTCL) express the tumour necrosis factor 
(TNF) receptor CD30, conferring cell survival and growth when activated through 
the NF-B pathway. Brentuximab vedotin (BV) is an antibody-drug conjugate 
(ADC) comprising an anti-CD30 monoclonal antibody and a microtubule-disrupt-
ing agent, monomethyl auristatin E (MMAE). Once bound to CD30 on tumour 
cells, BV is internalized by endocytosis and the MMAE released into the cytosol 
disrupts the microtubule network causing cell death 
Methodology  
Published and grey literature were identified by searching the Cochrane Library, 
CRD Database, Embase, Ovid Medline, PubMed, Internet sites and contacting the 
manufacturer.  Quality assessment was conducted to assess the risk of bias at the 
study level based on the EUnetHTA internal validity for randomized controlled 
trials.  
Results of the ECHELON-2 trial 
In the phase III, ECHELON-2 trial, 452 patients with untreated CD30-expressing 
PTCL were randomised 1:1 to receive BV (1.8 mg/kg IV) plus cyclophosphamide, 
doxorubicin, and prednisone (CHP) or cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) for six or eight 21-day cycles. At a median follow-
up of 42.1 months, the median OS was not reached for either group. BV+CHP 
conferred longer progression-free survival (PFS) than CHOP (PFS: 48.2 months 
versus 20.8 months), reducing the risk of death or progression by 29%. Greater 
objective response (OR) and complete remission (CR) rates were reported in 
BV+CHP patients compared with CHOP (ORR: 83% versus 72%; CRR: 68% ver-
sus 56%). Durable OR was achieved at all levels of CD30 expression among 
BV+CHP recipients, including those with 10% CD30 expression. No clinically 
meaningful differences in generic or disease-specific quality of life (QoL) scores 
were observed between groups. Treatment-related AEs of any grade reported in 
20% or more patients in the BV+CHP versus the CHOP group were was nausea, 
peripheral sensory neuropathy, neutropenia, diarrhoea, constipation, alopecia, py-
rexia, vomiting, fatigue, and anaemia. Discontinuation due to AEs occurred in 6% 
of patients in the BV+CHP group and 7% of CHOP patients. AEs leading to death 
occurred in 3% of patients in the B+CHP group and 4% of patients in the CHOP 
group.  
Conclusion 
Overall, ECHELON-2 is the first phase 3, randomised, double-blind, active com-
parator study to demonstrate that compared with CHOP, BV+CHP increases PFS, 
OR and CR in previously untreated CD30-positive PTCL patients. While the PFS 
benefits were generally consistent across subtypes, the study was not powered to 
compare efficacy between individual histological subtypes and small sample sizes 
preclude definitively determining the treatment effect in non-systematic ALCL. No 
clinically meaningful differences were noted in QoL measures. The development 
of a clinically validated in vitro diagnostic for CD30 expression may ensure the 
appropriate selection of patients most likely to benefit from BV+CHP therapy. Fur-
ther studies are needed to better define the efficacy of BV in non-ALCL histolo-
gies, optimal dosing to enhance disease control while limiting complications, opti-
mal therapeutic sequence, and use as monotherapy versus in combination with im-
mune checkpoint inhibitors or other immunomodulatory agents.   
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1 Research questions 
The HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharma-
ceuticals was used for structuring this report [1]. The Model organises HTA infor-
mation according to pre-defined generic research questions. Based on these generic 
questions, the following research questions were answered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is brentuximab vedotin? 
A0022 Who manufactures brentuximab vedotin? 
A0007 What is the target population in this assessment? 
A0020 For which indications has brentuximab vedotin received marketing authorisation? 
Health problem and current use 
A0002 What is peripheral T-cell lymphoma in the scope of this assessment? 
A0004 What is the natural course of peripheral T-cell lymphoma? 
A0006 What are the consequences of peripheral T-cell lymphoma for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of peripheral T-cell lymphoma? 
A0003 What are the known risk factors for peripheral T-cell lymphoma? 
A0024 
How is peripheral T-cell lymphoma currently diagnosed according to published guidelines 
and in practice? 
A0025 
How is peripheral T-cell lymphoma currently managed according to published guidelines 
and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of brentuximab vedotin on mortality? 
D0005 
How does brentuximab vedotin affect symptoms and findings (severity, frequency) of 
peripheral T-cell lymphoma? 
D0006 
How does brentuximab vedotin affect progression (or recurrence) of peripheral T-cell 
lymphoma? 
D0011 What is the effect of brentuximab vedotin on patients ̕ body functions? 
D0012 What is the effect of brentuximab vedotin on generic health-related quality of life? 
D0013 What is the effect of brentuximab vedotin on disease-specific quality of life? 
Safety 
C0008 How safe is brentuximab vedotin in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying brentuximab vedotin? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of brentuximab vedotin? 
A0021 What is the reimbursement status of brentuximab vedotin? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Brentuximab vedotin/Adcetris®/L01XC12 
 
B0001: What is brentuximab vedotin? 
Several peripheral T-cell lymphomas (PTCL) express the tumour necrosis factor 
(TNF) receptor CD30 that, upon activation through the NF-B pathway, confers 
cell growth and survival. Brentuximab vedotin (BV) is an antibody-drug conjugate 
(ADC) comprising anti-CD30 monoclonal antibody and a microtubule-disrupting 
agent, monomethyl auristatin E (MMAE). Once bound to CD30 on tumour cells, 
BV is internalized by endocytosis and the MMAE released into the cytosol disrupts 
the microtubule network causing cell death [2, 3].  
BV is available as single-use vials of 50 mg powder for reconstitution (5 mg/mL). 
It is administered as a 30-minute intravenous infusion (IV) at a dose of 1.8 mg/kg 
every three weeks, in combination with cyclophosphamide, doxorubicin and pred-
nisone (CHP) chemotherapy, for six to eight cycles. Previously untreated PTCL 
patients receive granulocyte colony-stimulating factor (G-CSF) prior to their first 
cycle of BV+CHP [3, 4]. 
Patients should be monitored for adverse events (AEs) when BV is given concom-
itantly with strong CYP3A inhibitors. BV is contraindicated with concomitant ble-
omycin due to pulmonary toxicity. Dose reduction may be necessary for patients 
with mild hepatic impairment, grade 2 motor neuropathy or grade 3 sensory neu-
ropathy. BV is not for use in patients with severe renal or hepatic impairment and 
should be discontinued in patients with grade 3 motor neuropathy or progressive 
multifocal leukoencephalopathy (PMJ) [3].  
 
A0022: Who manufactures brentuximab vedotin? 
Seattle Genetics, Inc in collaboration with Takeda Pharmaceutical Company 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Brentuxiumab vedotin (Adcetris®) is indicated, in combination with chemother-
apy, for previously untreated systemic anaplastic large cell lymphoma (sALCL) 
or other CD30-expressing PTCLs, including angioimmunoblastic T-cell lym-
phoma (AITL) and PTCL not otherwise specified (PTCL-NOS) [3]. 
 
 
anti-CD30 antibody 
conjugated with MMAE 
BV (1.8 mg/kg IV) every 
3 weeks + CHP for 6–8 
cycles 
monitor AEs if given 
concomitantly with 
CYP3A inhibitors, avoid 
bleomycin; reduce or 
discontinue for 
safety/tolerability 
previously untreated 
CD30-positive PTCL 
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4 Current regulatory status 
A0020: For which indications has brentuximab vedotin received marketing 
authorisation? 
In August 2011, the US Food and Drug Administration (FDA) granted accelerated 
approval of BV for the treatment of Hodgkin lymphoma (HL) after failure of au-
tologous stem cell transplant (ASCT) or two prior multi-agent chemotherapy regi-
mens in non-eligible ASCT candidates; and for sALCL after failure of at least one 
prior multi-agent chemotherapy. Approvals were based on the objective response 
rates (ORR) reported in two single-arm studies involving 102 HL patients and 58 
sALCL patients [5, 6]. In August 2015, BV was approved for the treatment of pa-
tients with HL at high risk of relapse or progression post-ASCT based on progres-
sion-free survival (PFS) data from the phase 3 AETHERA trial involving 329 pa-
tients [7]. The FDA expanded approval of BV as first-line treatment for stage III 
or IV HL in combination with doxorubicin, vinblastine, and dacarbazine (AVD) 
chemotherapy in March 2018. Approval was based on PFS data from the open-
label, phase 3 ECHELON-1 study involving 1,334 patients [8, 9]. 
BV was granted FDA breakthrough therapy designation for the treatment of pa-
tients with primary cutaneous anaplastic large cell lymphoma (CTCL) or CD30-
expressing mycosis fungoides (MF) following prior systemic therapy in November 
2017. The approval was based on the ORR reported in the phase 3, ALCANZA 
trial involving 128 CTCL and CD30-expressing MF patients [9-12].  
In November 2018, the FDA approved BV in combination with CHP chemother-
apy for previously untreated sALCL or other CD30-expressing PTCL, including 
AITL and PTCL-NOS. Under the Real-Time Oncology Review Pilot Program, ap-
proval occurred less than two weeks following the submission of PFS and overall 
survival (OS) data from the phase 3 ECHELON-2 study involving 452 patients [3, 
4, 13].  
BV received marketing authorisation by the European Medicine Agency (EMA) in 
October 2012, and is approved for the treatment of patients with relapsed or refrac-
tory (r/r) CD30-positive HL or sALCL, CD30-positive HL at increased risk of re-
lapse or progression following ASCT, and CD30-positive CTCL following sys-
temic therapy. In December 2018, the marketing authorisation of BV was extended 
to include the treatment of previously untreated CD30-positive stage IV HL in 
combination with AVD [9, 14]. BV is not currently indicated as first-line therapy 
for sALCL or other CD30-epressing PTCL in Europe [15].  
 
 
 
 
 
 
 
FDA: licensed second-
line for HL and sALCL 
from August 2011-2015 
FDA: expanded first-line 
in combination with 
AVD for stage III/IV HL 
in March 2018 
FDA: licensed second-
line for CTCL or CD30-
expressing MF in 
November 2017 
FDA: expanded first-line 
in combination with 
CHP for sALCL or CD30-
expressing PTCL in 
November 2018 
EMA: first-line in 
combination with AVD 
for CD30-positive stage 
IV HL; second-line for 
CD30-positive CTCL, 
sALCL, r/r HL or patients 
at risk of 
relapse/progression 
post-ASCT from 2012-
2018 
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5 Burden of disease 
A0002: What is peripheral T-cell lymphoma? 
Peripheral T-cell lymphoma (PTCL), a rare hematologic malignancy that develops 
from mature T-cells and natural killer (NK cells), accounts for approximately 10–
15% of non-Hodgkin lymphomas (NHL). While approximately 28 histological sub-
types have been identified, primary nodal PTCL accounts for more than 80% of Eu-
ropean cases [16, 17]. It is commonly classified as PTCL-not otherwise specified 
(PTCL-NOS) (34%), angioimmunoblastic T-cell lymphoma (AITL) (28%), and an-
aplastic large cell lymphoma (ALCL) that subdivides as anaplastic lymphoma kinase 
(ALK)-positive and ALK-negative (6% and 9% of cases, respectively) [17]. Ac-
counting for most PTCLs, PTCL-NOS represents a heterogeneous group of many not 
yet identified PTCL subtypes with no consistent immunophenotypic, genetic or clin-
ical features [17]. The cellular membrane protein CD30 is strongly expressed on ne-
oplasms but not on most normal cells, allowing for targeting by ADC-based BV ther-
apy [18]. CD30 is uniformly expressed in ALCL while expression by other PTCL 
subtypes ranges from 43% to 57% [19]. 
 
A0004: What is the natural course of peripheral T-cell lymphoma? 
PTCL develops when mature white blood cells, known as T-cells, undergo aberrant 
cell growth in lymphoid tissues outside of the bone marrow, such as the thymus, 
forming tumours in the mediastinum or lymphoid tissues. Virtually all cases of ALK-
positive ALCL are due to genetic translocations involving ALK [20]. To facilitate 
treatment, NHL is staged from I through IV based on tumour location. Stage I cancer 
occurs in a single lymph node, region, organ, or site; stage II occurs in two or more 
lymph nodes on the same side of the diaphragm; stage III involves lymph node re-
gions on both sides of the diaphragm, with or without partial involvement of an ex-
tranodal organ or site above or below the diaphragm; and stage IV has metastasized 
to bone marrow, spleen, liver, digestive system, skin or lungs [21].  
 
A0006: What are the consequences of peripheral T-cell lymphoma for the so-
ciety? 
Lymphoma is the most common blood cancer in Europe, and the fifth most com-
mon cancer after breast, lung, bowel and prostate cancers. Europe accounts for 
nearly 18–19% of all lymphoma mortality worldwide [22]. Comprising 5–10% of 
all lymphoid neoplasms, with the exception of ALK-positive ALCL and localized 
extranodal NK/T-cell lymphoma, PTCL is among the more aggressive lymphomas 
with poor prognosis [23]. Approximately 50% to 70% of patients present with 
stage III or IV advanced disease with peripheral, including mediastinal, and or ab-
dominal lymphadenopathy. Five-year OS for patients with ALK-negative ALCL, 
PTCL-NOS, and AITL are approximately 34%, 35%, and 36%, respectively [24].  
 
A0023: How many people belong to the target population? 
PTCL accounts for approximately 10–15% of all NHL. The age standardized inci-
dence rate for NHL in the European Standard Population was 15.5 per 100,000 
persons per year in 2013 [25]. In Austria, 726 men and 607 women were diagnosed 
with NHL in 2016; and 354 men and 293 women died due to NHL (7.6 per 100,000 
persons per year) [25]. Assuming this, approximately 133 to 200 Austrians may be 
PTCL: heterogeneous 
group of T-cell NHL 
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28% AITL, 6% ALK-
positive and 9% ALK-
negative ALCL 
 
CD30 expression: 
uniform in ALCL; 43–57 
% other subtypes 
staged I–IV by 
invasiveness 
 
malignant T-cells 
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system or skin 
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disease 
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diagnosed with PTCL each year. PTCL is twice as common in men than women, 
and has a median age at diagnosis of 60 years [26].  
 
A0005: What are the symptoms and the burden of disease or peripheral T-cell 
lymphoma? 
Symptoms of PTCL include enlarged lymph nodes in the neck, armpit or groin. 
Approximately 35% of patients experience B symptoms involving recurrent fever, 
night sweats, and weight loss. Other symptoms include loss of appetite, fatigue, 
dyspnoea, and skin rash. Most PTCL patients present with generalized lyphade-
nopathy, 38% have nodal disease only and 49% have nodal and extranodal disease. 
Hepatomegaly and splenomegaly occur in 17% and 24% of patients, respectively. 
Bone marrow involvement occurs in 20% of cases, as well as lactate dehydrogen-
ase (LDH) elevation (37%), anaemia (27%) and thrombocytopenia (10%) [20, 26].  
 
A0003: What are the known risk factors for peripheral T-cell lymphoma? 
Risk factors for NHL include autoimmune diseases, human immunodeficiency vi-
rus – acquired immunodeficiency syndrome (HIV/AIDS), infection with human T-
lymphotropic virus (HTLV-1) or Epstein-Barr virus (EBV), immunosuppressant 
medications, solvents, pesticides and fertilizers. Coeliac disease, psoriasis, and 
breast implants have been associated with an increased risk of ALCL [17, 27, 28].  
The International Prognostic Index (IPI) uses known risk factors to predict OS and 
guide clinical management. Age, stage III or IV disease, more than one lymph node 
involvement, elevated serum LDH and performance status are used to predict the risk 
of relapse [21].  
 
A0024: How is peripheral T-cell lymphoma currently diagnosed according to 
published guidelines and in practice? 
PTCL is diagnosed by a haematopathologist based on excisional lymph node bi-
opsy. Classification is difficult due to the wide spectrum of morphologic features 
and lack of robust immunohistochemical markers. According to the World Health 
Organization classification (WHO), distinction among PTCL subtypes requires in-
tegration of the clinical features, morphology, immunophenotype, and genetics. 
Histologic examination of the biopsy usually shows atypical lymphoid cells, loss 
of mature T-cell antigens CD5 or CD7, clonal T-cell receptor gene rearrangements, 
and a proportion of PTCL express CD30 [17]. Gene expression profiling distin-
guishes PTCL-NOS from ALK-negative ALCL and AITL [23]. Additional diag-
nostic tests, including blood tests, computerized tomography (CT) scans, positron 
emission tomography (PET) scans, magnetic resonance imaging (MRI) and bone 
marrow biopsy may be useful to confirm diagnosis. Approximately 14% of PTCL 
cases are stage I, 17% are stage II, 26% are stage III, and 43% are stage IV at 
diagnosis [26].  
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6 Current treatment 
A0025: How is peripheral T-cell lymphoma currently managed according to 
published guidelines and in practice? 
PTCL are a heterogeneous group of mature, aggressive T-cell lymphomas and 
there is no general consensus regarding the optimal treatment regimen. Patients are 
stratified based on tumour expression of CD30, and are encouraged to participate 
in clinical trials. Newly diagnosed PTCL patients are typically treated with an-
thracycline-based chemotherapy regimens [21, 26]: 
 Cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for pa-
tients >60 years of age or less medically fit 
 Cyclophosphamide, hydroxydoxorubicin, vincristine, etoposide and predni-
sone (CHEOP) for patients 60 years of age 
 Etoposide, prednisone, vincristine, cyclophosphamide, and hydroxydoxorubi-
cin (EPOCH) 
 Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexame-
thasone (Hyper-CVAD) 
 ASCT or radiation therapy may be used as consolidation depending on the lym-
phoma subtype.  
 
 
7 Evidence 
A literature search was conducted on 19 April 2019 in five databases: the Cochrane 
Library, CRD Database, Embase, Ovid Medline and PubMed. Search terms were 
“brentuximab vedotin”, “Adcetris”, “peripheral T-cell lymphoma”, “PTCLs” and 
“CD30 positive”. The manufacturer was also contacted and submitted 13 refer-
ences, five of which had not already been identified by systematic literature search 
[29-33]. A manual search identified two statistical reports [22, 25], one FDA label 
[3], two EMA marketing authorization documents [14, 15], two clinical guidance 
documents [17, 26], two clinical trial documents [7, 8], and a cost document [34].  
Overall, 118 references were identified. Included in this reported are:  
 ECHELON-2, phase III [3, 4, 29, 30, 32, 35] 
 Frontline BV with CHP for CD30-expressing PTCL, phase I [36, 37] 
To assess the risk of bias at the study level, the assessment of the methodological 
quality of the evidence was conducted based on the EUnetHTA internal validity 
for randomised controlled trials (RCTs) [38]. Evidence was assessed based on the 
adequate generation of the randomisation sequence, allocation concealment, blind-
ing of patient and treating physician, selective outcome reporting and other aspects 
that may increase the risk of bias. Study quality details are reported in Table 5 of 
the Appendix. 
The external validity of the included trials was assessed using the EUnetHTA 
guideline on applicability of evidence in the context of a relative effectiveness as-
sessment of pharmaceuticals, considering the following elements: population, in-
tervention, comparator, outcomes and setting [39]. 
no consensus regarding 
optimal therapy; 
anthracycline-based 
chemotherapy 
first-line: CHOP, 
CHEOP, EPOCH, hyper-
CVAD,  
ASCT or radiotherapy as 
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systematic literature 
search in 5 databases:  
103 hits 
 
 
manual search: 15 
additional references 
overall: 118 references 
included: 2 studies 
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The evaluation of the magnitude of “meaningful clinically benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit Scale 
developed by the European Society for Medical Oncology (ESMO-MCBS) was 
not applied, since it can only be used for the evaluation of solid tumour drugs [40].  
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external reviewer. 
The latter was asked for the assessment of the following quality criteria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in clinical 
practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence, and amount of eligible pa-
tients correct? 
 Are the investigated studies correctly analysed and presented (data ex-
traction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly interpreted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from differ-
ent disciplines a method of quality assurance of scientific work. The final version 
and the policy recommendations are under full responsibility of the LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III studies 
ECHELON-2 (NCT02165397) is a multicentre, double-blind, double-dummy, ran-
domised, placebo-controlled, interventional phase III trial involving 452 patients 
with previously untreated sALCL and CD30-expressing PTCL [4]. The study was 
designed to compare the safety and efficacy of BV+CHP versus CHOP for the 
treatment of CD30-positive PTCL using a double-dummy method of blinding 
where both treatment groups received a placebo. Efficacy analyses were based on 
all randomly assigned patients comprising the intent-to-treat (ITT) population. 
Safety analyses involved all patients who received any amount of BV or any com-
ponent of CHOP. 
Eligible patients were 18 years or older, with newly diagnosed, centrally-confirmed 
CD30-positive (10% of cells) PTCL, measureable disease of 1.5 cm by CT, with 
an Eastern Cooperative Oncology Group (ECOG) performance status 2. Histolo-
gies were limited to ALK-positive sALCL (IPI 2), ALK-negative sALCL, PTCL-
NOS, AITL, adult T-cell leukaemia or lymphoma (ATLL), enteropathy associated 
with T-cell lymphoma and hepatosplenic T-cell lymphoma. Patients were excluded 
if they had a history of another primary invasive cancer, haematological malig-
nancy or previous treatment with BV. Study participants were stratified by histo-
logical subtype according to local pathology assessment (ALK-positive sALCL 
versus all other histologies, and baseline IPI score (0–1 versus 2–3 versus 4–5).  
ESMO-MCBS could not 
be assessed 
internal and external 
review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
ECHELON-2: BV+CHP 
versus CHOP for CD30-
positive PTCL 
ITT (n = 452): stratified 
by histological subtype 
and baseline IPI score 
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Patients were randomised 1:1 to BV+CHP or CHOP for six or eight 21-day cycles. 
All patients received cyclophosphamide (750 mg/m2 IV) and doxorubicin (50 
mg/m2 IV) on day 1, and prednisone (100 mg once daily) on days 1 to 5 of each 
cycle, with either BV (1.8 mg/kg) and placebo vincristine (IV) (BV+CHP group) 
or vincristine (1.4 mg/m2) and placebo BV (IV) (CHOP group) on day 1 of each 
cycle. Patients received granulocyte colony-stimulating factor (G-CSF) prior to 
their first BV+CHP cycle [35]. BV was reduced to a dose of 1.2 mg/kg for patients 
with mild hepatic impairment, grade 2 motor neuropathy or grade 3 sensory neu-
ropathy; and discontinued in those with grade 3 motor neuropathy [3, 35]. Ap-
proximately 89% of BV+CHP patients and 81% of CHOP patients received six or 
more cycles. The median relative dose intensity was 99.2% (interquartile range 
(IQR) 93.6–100.0) for BV in the BV+CHP group and 99.1% (IQR 95.9–102.3) for 
vincristine in the CHOP group. Consolidative stem cell transplant or radiotherapy 
was permitted following treatment at the investigators’ discretion [4].  
Assuming a median PFS of 23.9 months for the BV+CHP group and 16.5 months 
for the CHOP group, an estimated 238 PFS events would give the trial 80% power 
to detect a hazard ratio (HR) for disease progression or death of 0.6895 at a one-
sided significance of 0.025. Patients were enrolled between January 2013 and No-
vember 2016; by the data cut-off date for primary analysis, 219 PFS events had 
occurred. Excluding stem cell transplantation or radiotherapy for consolidation of 
response to initial therapy, 59 (26% of) BV+CHP patients and 94 (42% of) CHOP 
patients received subsequent anticancer therapies for residual or progressive dis-
ease. Approximately 23 (10% of) BV+CHP patients and 49 (22% of) CHOP pa-
tients received BV-containing subsequent therapy.  
The primary endpoint of PFS, defined as the time from randomisation until pro-
gression, subsequent anticancer chemotherapy or death, was assessed by blinded 
independent central review (BICR). Secondary endpoints were BICR-assessed 
PFS for patients with sALCL, ORR, complete remission rate (CRR), OS and 
safety. Exploratory analyses examined the relationship between CD30 expression, 
overall response (OR) and duration of response (DOR) [29]. Lymphoma response 
and progression were assessed according to the 2007 Revised Response Criteria 
for Malignant Lymphoma. Radiographical evaluations were submitted to BICR for 
masked review. CT and PET scans were performed at screening, after cycle 4, at 
the end of treatment, at 9, 12, 15, 18, 21 and 24 months, and every 6 months there-
after until progression or death. Safety outcomes were defined according to the 
Medical Dictionary for Regulatory Activities (MedDRA) version 21.0, and the Na-
tional Cancer Institute Common Terminology Criteria for Adverse Events, 
(CTCAE) version 4.03.  
The ITT population (n = 452) had a median age of 58 years (range 45–67), 63% 
were male, 62% were Caucasian, 27% had stage 3 disease, 53% had stage 4 dis-
ease, and 78% had IPI 2. The population was comprised of 70% sALCL (48% 
ALK-negative, 22% ALK-positive), 16% PTCL-NOS, 12% AITL, 2% adult T-cell 
leukaemia or lymphoma (ATLL), and 1% enteropathy-associated T-cell lymphoma 
(EATL). Detailed patient characteristics including inclusion- and exclusion criteria 
can be found in Fehler! Verweisquelle konnte nicht gefunden werden. and study 
quality is described in Fehler! Verweisquelle konnte nicht gefunden werden. of 
the appendix, respectively. Clinical efficacy data are presented in Table 1 and AEs 
are listed in Table 2.  
 
 
1.8 mg/kg IV BV+CHP 
versus placebo+CHOP 
89% of BV+CHP and 
81% of CHOP patients 
received >6 cycles 
death/progression at 
data cut-off: 219 
10% of BV+CHP and 
22% of CHOP patients 
received subsequent 
therapy containing BV  
primary endpoint: BICR-
assessed PFS 
 
secondary endpoints: 
BICR-assessed PFS for 
patients with sALCL, 
ORR, CRR, OS and 
safety 
 
exploratory endpoint: 
relationship between 
CD30 expression, OR 
and DOR  
ITT: mean age 58 years, 
63% male, 80% stage 
III/IV, 78% IPI 2 
 
histology: 70% sALCL, 
16% PTCL-NOS, 12% 
AITL, 2% ATLL, and 1% 
EATL 
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7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of brentuximab vedotin on mor-
tality? 
By the cut-off date for the primary analysis, 124 deaths had occurred; 51 (23%) in 
the BV+CHP group and 73 (32%) in the CHOP group. After a median follow-up 
of 42.1 months (95% CI 40.4–43.8), the median OS was not reached for either 
group. The 75th percentile OS was not reached for the BV+CHP group but was 17.5 
months for the CHOP group. BV+CHP reduced the risk of death by 34% compared 
with CHOP (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.46–0.95; p = 
0.0244). The OS benefit of BV+CHP over CHOP was consistent across histologi-
cal subtypes based on the overlapping of confidence intervals with those of the ITT 
population [4, 35]. 
 
D0006: How does brentuximab vedotin affect progression (or recurrence) of 
peripheral T-cell lymphoma? 
At a median follow-up of 36.2 months, the primary endpoint of BICR-assessed 
median PFS was 48.2 months (95% CI 35.2–not estimable [NE]) in the BV+CHP 
group versus 20.8 months (95% CI 12.7–47.6) in the CHOP group (HR 0.71, 95% 
CI 0.54–0.93; p = 0.0110). The 3-year PFS was 57.1% (95% CI 49.9–63.7) for the 
BV+CHP group versus 44.4% (95% CI 37.6–50.9) for the CHOP group [4, 35]. 
 
Pre-specified analyses of PFS were similar to those of the primary analysis of PFS. 
The HR for BICR-assessed PFS for which consolidative stem cell transplantation 
or consolidative radiotherapy was censored was 0.71 (95% CI 0.53–0.94; p = 
0.017) [4, 29]. BICR-assessed PFS for sALCL patients was consistent with results 
of the primary analysis (HR 0.59, 95% CI 0.42–0.84; p = 0.0031). The PFS anal-
yses by subtype were generally consistent with the overall study results. ALK-pos-
itive sALCL had the lowest HR, ALK-negative sALCL, and PCL-NOS were sim-
ilar to the ITT population, and AITL was above unity. However, the study was not 
powered to compare efficacy between individual histological subtypes [4].  
 
D0005: How does brentuximab vedotin affect symptoms and findings (sever-
ity, frequency) of peripheral T-cell lymphoma? 
The secondary endpoint of BICR-assessed ORR in the ITT population was 83% 
(95% CI 77.7–87.8) in the BV+CHP group and 72% (95% CI 65.8–77.9) in the 
CHOP group (response rate difference [RRD] 11.1, 95% CI 3.4–18.7; p = 0.0032). 
Complete remission was reported in 68% (95% CI 61.2–73.7) of BV+CHP recipi-
ents and 56% (95% CI 49.0–62.3) of CHOP recipients (RRD 11.9, 95% CI 3.1–
20.8; p = 0.0066). CRR and DOR in patients with AITL (p = 0.84, p = 0.30, re-
spectively) and PTCL-NOS (p = 0.44, p = 0.90, respectively) were independent of 
the level of CD30 expression [30]. Durable OR was achieved at all levels of CD30 
expression among BV+CHP recipients, including those with CD30 expression of 
10% [29].  
Excluding consolidation therapy for initial treatment, 26% of BV+CHP patients 
and 42% of CHOP patients received subsequent anticancer therapies for residual 
or progressive disease; 10% of the BV+CHP group and 22% of the CHOP group 
received subsequent therapy containing BV [4].  
median OS: not reached 
in either group 
 
75% percentile OS: 
BV+CHP: not reached 
CHOP: 17.5 months 
 
OS benefit consistent 
across subtypes 
median PFS:  
BV+CHP: 48.2 months 
CHOP: 20.8 months 
3-year PFS: 
BV+CHP: 57.1% 
CHOP: 44.4% 
 
PFS benefit generally 
consistent across 
histological subtypes 
 
ORR ITT: 
BV+CHP: 83% 
CHOP: 72%  
 
durable response at all 
levels of CD30 
expression 
 
CRR:  
BV+CHP: 68%  
CHOP: 56%  
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D0011: What is the effect of brentuximab vedotin on patients̕  body functions? 
BV may cause peripheral neuropathy, anaphylaxis, infusion reactions, serious in-
fections, tumour lysis syndrome (TLS), dermatologic reactions, gastrointestinal 
(GI) complications, and toxicities of the blood, liver, lung, embryo or foetus [3]. 
Approximately 52% of BV+CHP-treated patients experienced new or worsening 
peripheral neuropathy; 94% sensory and 16% motor, with a median onset of 2 
months (range, <1–5) and a median time to improvement of 4 months (range, 0–
45) [4]. Patients should be monitored for symptoms of neuropathy such as hypoes-
thesia, hyperesthesia, paraesthesia, discomfort, burning, neuropathic pain or weak-
ness. Infusions may be interrupted or discontinued in the case of infusion reaction 
or anaphylaxis.  
Serious febrile neutropenia, grade 3 or 4 thrombocytopenia may occur with BV. 
Patients require G-CSF prophylaxis prior to starting their first BV+CHP cycle, and 
complete blood count (CBC) monitoring prior to each BV dose. Liver enzymes and 
bilirubin should be checked periodically for hepatotoxicity. Patients with highly 
proliferating tumours should be monitored for tumour lysis syndrome; and those 
with new-onset central nervous system abnormalities or epidermal necrosis should 
discontinue BV in the case of progressive multifocal leukoencephalopathy (PML) 
or Stevens-Johnson syndrome (SJS). BV may cause embryo-foetal harm based on 
its mechanism of action. Females are advised to avoid pregnancy during BV treat-
ment and for at least six months after the final dose.  
D0012: What is the effect of brentuximab vedotin on generic health-related 
quality of life? 
No clinically meaningful differences were noted in the mean change in EQ-5D 
from baseline over time between groups [29].  
 
 
D0013: What is the effect of brentuximab vedotin on disease-specific quality 
of life? 
At baseline, the mean European Organization for Research and Treatment of Can-
cer Quality of Life Questionnaire (EORTC QLQ-30) functional, symptom, and 
global health scores were lower in the BV+CHP than the CHOP group. During 
treatment, the scores improved in both groups and returned to near normal values 
in long-term follow-up. No clinically meaningful differences were observed in the 
functional and global health scores between groups. With the exception of diar-
rhoea at cycle seven, none of the differences in the other symptom scores across 
cycles were clinically meaningful based on the published minimally important dif-
ference (MID) of ten. No clinically meaningful differences were found in the mean 
change in the Functional Assessment of Cancer Treatment Gynecologic Oncology 
Group-Neurotoxicity (FACT/GOG-NTX) subscale scores between treatment 
groups during treatment [29].  
 
 
 
 
 
 
peripheral neuropathy, 
anaphylaxis, infusion 
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blood, liver, lung, and 
foetus  
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enzymes, and bilirubin 
 
prophylactic: G-CSF 
prior to BV+CHP  
 
generic health-related 
QoL: no clinically 
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Table 1: Efficacy results of ECHELON-2 [3, 4, 29, 32, 35] 
Descriptive sta-
tistics and 
estimate varia-
bility 
Treatment group 
BV+CHP 
(n = 226) 
CHOP 
(n = 226) 
Deaths, n (%) 
OS, m (95% CI) 
51 (23) 
NR (NR–NR) 
73 (32) 
NR (54.2–NR ) 
PFS events, n (%) ITT (n = 452) 
BICR-assessed median PFS, m (95% CI) ITT 
   36 m PFS, m (95% CI) ITT 
Events 
   Death 
   Subsequent anticancer chemotherapy for residual or progression 
95 (42) 
48.2 (35.2–NR) 
57.1 (49.9–63.7) 
 
13 (6) 
11 (5) 
124 (55) 
20.8 (12.7–47.6) 
44.4 (37.6–50.9) 
 
17 (8) 
21 (9) 
PFS events, n (%) sALCL (n = 314) 
BICR-assessed median PFS, m (95% CI) sALCL 
56 (34) 
55.7 (48.2–NR) 
73 (48) 
54.2 (13.4–NE) 
ORR, % (95% CI), p-value 83 (78–88) 72 (66–78) 
CRR, % (95% CI), p-value 68 (61–74) 56 (49–62) 
Effect  
estimate per 
comparison 
 
Comparison groups                                                                                    BV+CHP versus CHOP 
BICR-assessed PFS (n = 452) 
(primary endpoint) 
HR  0.71 
95% CI 0.54–0.93 
Log-rank test p-value 0.011 
PFS, sALCL  
(subgroup analysis, n = 314) 
HR  0.59 
95% CI 0.42–0.84 
Log-rank test p-value 0.003 
PFS, ALK-positive sALCL 
(subgroup analysis, n = 98) 
HR  0.29 
95% CI 0.11–0.79 
Log-rank test p-value NA 
PFS, ALK-negative sALCL 
(subgroup analysis, n = 218) 
HR  0.65 
95% CI 0.44–0.95 
Log-rank test p-value NA 
PFS, AITL 
(subgroup analysis, n = 54) 
HR  1.40 
95% CI 0.64–3.07 
Log-rank test p-value NA 
PFS, PTCL-NOS 
(subgroup analysis, n = 72) 
HR  0.75 
95% CI 0.41–1.37 
Log-rank test p-value NA 
OS (n = 452) 
(secondary endpoint) 
HR  0.66 
95% CI 0.46–0.95 
Log-rank test p-value 0.024 
Mean change in EQ-5D from baseline Difference between 
groups 
No meaningful differ-
ence 
EORTC QLQ-30 functional and global scores Difference between 
groups 
No meaningful differ-
ence 
Mean change in FACT/GOG-NTX Difference between 
groups 
No meaningful differ-
ence 
Abbreviations: ALK = anaplastic lymphoma kinase, AITL = angioimmunoblastic T-cell lymphoma; BICR = blinded independent central review; CI = confidence 
interval; CRR = complete remission rate; EORTC QLQ-30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; 
FACT/GOG-NTX = Functional Assessment of Cancer Treatment Gynecologic Oncology Group-Neurotoxicity; HR = hazard ratio; m = months; n = number; NA 
= not available; NR = not reached; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PTCL-NOS = peripheral T-cell 
lymphoma-not otherwise specified; sALCL = systemic anaplastic large cell lymphoma 
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7.2.2 Safety 
 
C0008: How safe is brentuximab vedotin in relation to the comparator(s)? 
In the safety population (n = 449), the most common AEs of any grade occurring 
in 20% of patients in the safety population, and more commonly reported in the 
BV+CHP than CHOP groups, respectively included nausea (46% versus 38%), pe-
ripheral sensory neuropathy (45% versus 41%), diarrhoea (38% versus 20%), alo-
pecia (26% versus 25%), pyrexia (26% versus 19%), vomiting (26% versus 17%), 
fatigue (24% versus 20%) and anaemia (21% versus 16%). Approximately 52% 
BV+CHP patients and 55% of CHOP patients reported peripheral neuropathy, of 
which 50% and 64%, respectively, resolved within a median of 17 weeks. Consti-
pation (29% versus 30%) was less commonly reported in BV+CHP than CHOP 
recipients [4].  
Grade 3 AEs and SAEs were similar between groups (66% versus 65%, 39% ver-
sus 38%, BV+CHP versus CHOP groups, respectively). The incidence of grade 3 
neutropenia was similar between groups (38% versus 38%, BV+CHP versus 
CHOP, respectively), and lower in patients receiving primary prophylaxis with G-
CSF (13% versus 13%, G-CSF with BV+CHP or CHOP, respectively) [35]. Fe-
brile neutropenia was reported in 18% of BV+CHP recipients and 15% of CHOP 
recipients. Grade 3 infections were reported in 19% of patients in the BV+CHP 
group and 14% of patients in the CHOP group. Approximately two BV+CHP re-
cipients and one CHOP recipient experienced ongoing grade 3 peripheral neurop-
athy at the last follow-up. AEs that resulted in death occurred in seven (3% of) 
BV+CHP patients and nine (4% of) CHOP patients [4].  
 
C0002: Are the harms related to dosage or frequency of applying brentuximab 
vedotin? 
The median duration of treatment (DOT) was 18.1 months (range 3.0–34.0) for 
BV+CHP and 18.0 months (range 3.0–31.0) for CHOP. Patients in both groups 
received a median of six treatment cycles (range 1–8) [35]. SAEs occurring in >2% 
of BV+CHP recipients included febrile neutropenia (14%), pneumonia (5%), py-
rexia (4%), and sepsis (3%). In the BV+CHP group, AEs leading to dose delays 
occurred in 25% of patients, while 9% experienced AEs requiring dose reduction, 
primarily due to peripheral neuropathy. Approximately 6% of BV+CHP recipients 
and 7% of CHOP recipients discontinued treatment due to AEs, most commonly 
from peripheral neuropathy and infection [3, 4]. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of brentuximab vedotin? 
BV is not advised for use in patients with severe hepatic or renal impairment [3]. 
Patients with a history of another primary invasive cancer, haematological malig-
nancy, peripheral neuropathy, symptomatic cardiac disease, or active infection 
were excluded from the trial population. Study participants had a median age of 58 
years (range 44–67) with a good performance status (ECOG 0–1) and an IPI score 
of 3 [4]. Approximately 31% of BV+CHP-treated patients were older than 65 
years of age. Among older patients, 74% had grade  
common AEs: nausea, 
peripheral neuropathy, 
diarrhoea, alopecia, 
pyrexia, vomiting, 
fatigue, and anaemia  
common grade 3 AEs: 
neutropenia, infections, 
and peripheral 
neuropathy  
deaths due to AEs:  
BV+CHP: 3% 
CHOP: 4%   
6% discontinued, 9% 
reduced dose, and 25% 
delayed BV+CHP due to 
AEs: peripheral 
neuropathy and 
infection 
susceptibles: elderly, 
hepatic or renal 
impairment 
 
common AEs in elderly: 
febrile neutropenia 
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3 AE and 49% had SAE. Of the patients less than 65 years of age, 62% experi-
enced grade 3 AE and 33% had SAE. Febrile neutropenia occurred in 29% of 
patients older than 65 years of age and 14% of those less than 65 years of age [3]. 
BV may cause embryo-foetal harm and potential for SAEs in nursing infants. Fe-
males are advised that breastfeeding is not recommended during BV+CHP treat-
ment. Males and females are advised to use effective contraception during 
BV+CHP treatment and for at least six months following their last dose.  
 
Table 2: Most frequent adverse events in 20% of the safety population [4] 
Adverse Event (according  
to MedDRA version 21.0 and 
CTCAE version 4.03) 
B+CHP 
(n = 223) 
CHOP 
(n = 226) 
20% of patients  
Any Grade 
n (%) 
Grade 3 
n (%) 
Any Grade  
n (%) 
Grade 3 
n (%) 
Any AE 
Grade ≥ 3 AE 
SAE 
Discontinued due to AE 
Deaths due to AE 
221 (99) 
147 (66) 
87 (39) 
14 (6) 
7 (3%) 
221 (98) 
146 (65) 
87 (38) 
15 (7) 
9 (4) 
Nausea 103 (46) 5 (2) 87 (38) 4 (2) 
Peripheral sensory 
neuropathy 
110 (45) 8 (4) 92 (41) 6 (3) 
Neutropenia 85 (38) 77 (35) 85 (38) 76 (34) 
Diarrhoea 85 (38) 13 (6) 46 (20) 2 (1) 
Constipation 64 (29) 2 (1) 67 (30) 3 (1) 
Alopecia 58 (26) 0 (0) 56 (25) 3 (1) 
Pyrexia 58 (26) 4 (2) 42 (19) 0 (0) 
Vomiting 57 (26) 2 (1) 39 (17) 4 (2) 
Fatigue 54 (24) 2 (1) 46 (20) 4 (2) 
Anaemia 46 (21) 30 (13) 36 (16) 23 (10) 
Abbreviations: AE = adverse event; CTCAE = Common Terminology for Cancer Adverse Events; MedDRA = Medical Dictionary 
for Regulatory Activities; SAE = serious adverse event 
 
 
7.3 Clinical effectiveness and safety –  
further studies 
NCT01309789 is a multicentre, open-label, dose escalation, phase 1 trial to evalu-
ate the safety of BV as first-line treatment for CD30-positive PTCL administered 
either sequentially (n = 13) or in combination with chemotherapy (n = 26). The 
sequential treatment group received BV 1.8 mg/kg (two cycles, once every three 
weeks, IV), followed by CHOP (six cycles, once every three weeks, IV). The com-
bination group received BV 1.8 mg/kg plus CHP (six cycles, once every three 
weeks, IV). Vincristine was omitted from combination treatment to reduce poten-
tial neurotoxicity. The combination treatment group included six patients with 
sALCL to determine the maximum-tolerated dose (MTD) of BV in combination 
with CHP. The initial dose of BV was 1.8 mg/kg; enrolment of patients would 
continue at that dose if one or fewer dose-limiting toxicities were observed. Pa-
tients with an OR at the end of treatment could receive single-agent BV for eight 
BV may cause embryo-
foetal harm  
 
NCT01309789: First-line 
BV administered 
sequentially or in 
combination with 
chemotherapy for CD30-
positive PTCL  
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to ten additional cycles. The sponsor terminated enrolment in the sequential-treat-
ment group after observing patients who initially responded to BV experience dis-
ease progression while receiving CHOP.   
The primary endpoint was incidence of AEs. Secondary outcomes included ORR, 
CRR, PFS, and OS. For the sequential-treatment group, responses were assessed 
by CT/PET scan after two cycles of single-agent BV and again after six cycles of 
CHOP, according to the Revised Response Criteria for Malignant Lymphoma. For 
the combination-treatment group, responses were assessed by CT/PET after six 
combination treatment cycles. Scans were performed after subsequent single-agent 
BV maintenance treatment. Patients were assessed for survival and clinical pro-
gression every three months until death or study closure. AEs were summarised 
using MeDRA, version 14.0, and graded using (CTCAE) version 3.0.  
The study population had a median age of 57 years (range 21–82), 51% were male, 
67% were Caucasian, 44% had stage 4 disease, and 67% had IPI 2. The popula-
tion was comprised of 82% sALCL (67% ALK-negative, 15% ALK-positive), 5% 
PTCL-NOS, 5% AITL, 5% ATLL, and 3% EATL. CD30 expression in the tumour 
cells of non-ALCL patients ranged from 20% to 98%. ALK-negative patients were 
older than ALK-positive patients (median age 60 versus 35 years).  
After sequential treatment, eleven (85%) of 13 patients achieved an OR (CRR 
62%; PRR 23%). Median PFS was 22.1 months (95% CI 8.8–NE), with a 1-year 
PFS rate of 77% (95% CI 44–92). Median OS was not reached, and the estimated 
1-year OS rate was 85% (95% CI 51–96). After combination therapy, 26 (100%) 
of 26 patients achieved an OR (CRR 88%; PRR 12%). All seven non-ALCL pa-
tients achieved CR. Following a median of 21.4 months, median PFS had not been 
reached (95% CI 11.7–NE), and the estimated 1-year PFS rate was 71% (95% CI 
49–85). Median OS was not reached, and the estimated 1-year OS rate was 88% 
(95% CI 68–96) [37]. At five years, neither the median PFS or OS was reached, 
estimated 5-year PFS and OS rates were 52% and 80%, respectively [36]. 
Sequential treatment-related AE of  grade 3 severity occurred in eight (62%) of 
13 patients, SAEs occurred in six (46%) of 13 patients, and two (15%) of patients 
discontinued treatment due to AEs. Combination treatment-related AEs of any 
grade (incidence 30), included peripheral sensory neuropathy (PSN) (69%), nau-
sea (65%), fatigue (58%), diarrhoea (58%), alopecia (54%), dyspnoea (46%), con-
stipation (38%), peripheral oedema (35%), and anaemia, chills, febrile neutropenia, 
upper respiratory tract infection, and myalgia (31% each). Grade 3 AE were ob-
served in 73% of patients; febrile neutropenia (31%), neutropenia (23%), anaemia 
(15%), and pulmonary embolism (PE) (12%) occurred in at least 10% of patients. 
SAEs were reported in 50% of patients; febrile neutropenia (31%), pyrexia (8%), 
and cardiac failure (8%). Six (23%) of 26 patients discontinued treatment due to 
an AE, half during combination treatment and half during single-agent mainte-
nance [37]. At 5 years, 18 (95%) of 19 BV+CHP recipients reported a resolution 
or improvement in the symptoms of treatment-related neuropathy [36].  
 
 
 
 
primary endpoint: AE 
 
secondary endpoints: 
ORR, CRR, PFS and OS 
cohort: 57 years of age, 
44% stage IV 
 
histology: 82% sALCL, 
5% PTCL, 5% AITL, 5% 
ATLL, 3% EATL 
 
sequential treatment:  
ORR: 85%,  
PFS rate: 77% 
OS rate: 85% 
 
combination treatment: 
ORR: 100% 
PFS rate: 71% 
OS rate: 88% 
AE: PSN, nausea, 
anaemia, diarrhoea, PE, 
dyspnoea, febrile 
neutropenia, infection 
 
sequential treatment:  
grade 3 AE: 62% 
SAE: 46% 
discontinued: 15% 
 
combination treatment: 
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8 Estimated costs 
A0021: What is the reimbursement status of brentuximab vedotin? 
In Austria, single-use vials of 50 mg BV powder for reconstitution, as a single-
dose solution containing 5 mg/mL BV, are available at a cost of € 3,333.00 (ex-
factory price) [34]. Based on a study dose of 1.8 mg/kg and assuming an average 
body weight of 70 kg, one dose of BV would cost approximately € 9,999.00, every 
three weeks in combination with CHP. Six cycles of BV+CHP would cost approx-
imately € 59,994.00 plus the additional cost of CHP. BV is indicated for the treat-
ment of previously untreated sALCL or other CD30-expressing PTCL, including 
AITCL and PTCL-NOS, in combination with CHP. Assuming approximately 133 
to 200 Austrians may be diagnosed with PTCL each year, BV would cost approx-
imately € 7,979,202.00 to € 11,998,800.00 (six cycles of treatment) annually with 
additional costs for G-CSF prophylaxis, chemotherapy and gene expression profil-
ing.  
 
 
9 Ongoing research 
Several studies are ongoing to investigate BV as monotherapy or in combination 
with other therapies, as induction, first-line, second-line, salvage or consolidation 
therapy for PTCL. In June 2019, searches of www.clinicaltrials.gov and www.clin-
icalrialsregister.eu using the search terms “brentuximab vedotin” and “peripheral 
T-cell lymphoma” yielded ten other registered studies (seven phase 2, one phase 
1/2, and two phase 1 studies). Most studies were industry-sponsored or conducted 
in collaboration with industry.  
Selected recently completed and ongoing phase 2 or 1 studies evaluating BV as 
induction therapy in combination with cyclophosphamide, doxorubicin, etoposide, 
and prednisone (CHEP), first-line monotherapy in the elderly, first-line in combi-
nation with rituximab, as monotherapy for low CD30 expressing r/r PTCL, mono-
therapy for r/r PTCL following gemcitabine or BV, or in combination with lenalid-
omide or bendamustine for r/r PTCL: 
 NCT01805037: is a phase 2, open-label, single-group, interventional 
study to evaluate the safety and effectiveness of combination BV and 
rituximab in CD30-positive and or EBV-positive lymphomas. Estimated 
study completion date January 2016.  
 NCT03113500: is a phase 2, open-label, single-group, interventional trial 
to assess the safety and tolerability of cyclophosphamide, doxorubicin, 
etoposide, prednisone and BV (CHEP-BV) as induction therapy in CD30-
positive PTCL patients, followed by BV consolidation. Estimated study 
completion date December 2019.  
 NCT03302728: is a phase 1, open-label, single-group, dose-escalation, 
interventional study to investigate the combination of BV and lenalido-
mide for the treatment of r/r cutaneous T-cell lymphoma, and CD30-pos-
itive PTCL or HL. Estimated study completion date August 2021.  
€ 9,999.00 /cycle, 
additional costs for G-
CSF, chemotherapy and 
genetic profiling 
 
six cycles of BV:  
~ € 59,994.00 
10 registered studies 
7 phase 2 studies 
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 NCT02499627: is a phase 2, multicentre, open-label, single-group, inter-
ventional trial designed to evaluate the efficacy and safety of combination 
bendamustine and BV as first salvage therapy in patients with r/r HL or 
PTCL. Estimated study completion date October 2021.  
 NCT0249731: is a phase 2, multicentre, open-label, single-group, inter-
ventional study to evaluate the efficacy of BV as a single agent for the 
treatment of r/r CD30-positive PTCL. Estimated study completion date 
December 2021.  
 NCT03496779: is a phase 2, multi-centre, open-label, single-group, in-
terventional trial to determine the efficacy of BV in patients treated with 
gemcitabine for r/r PTCL in terms of ORR after four cycles of treatment. 
Estimated study completion date October 2022.  
 NCT02588651: is a phase 2, open-label, single-group, interventional 
study to investigate BV monotherapy for r/r low CD30-expressiong 
(<10%) PTCL. Estimated study completion date December 2022.  
 NCT01716806: is a phase 2, open-label, non-randomised, interventional 
study to evaluate the efficacy of first-line BV as monotherapy in CD30-
expressing PTCL and in combination with other agents (bendamustine, 
dacarbazine or nivolumab) for HL in patients 60 years of age or older. 
Estimated study completion date September 2024.  
 NCT03947255: is a phase 2, multicentre, open-label, single-group, inter-
ventional trial to assess the safety and efficacy of BV in patients with HL, 
sALCL or other CD3-expressing PTCL who experienced CR or PR with 
BV-containing regimen and subsequently experienced progression or re-
lapse. Estimated study completion date December 2024.  
 
 
10 Discussion 
Between 2011 and 2018, both the FDA and the EMA licensed BV for the treatment 
of patients with CD30-positive r/r HL or sALCL, HL at increased risk of relapse 
or progression following ASCT, CTCL following systemic therapy, and previously 
untreated stage IV HL in combination with AVD [3, 14, 15]. Approvals were based 
on data from two phase 2 studies [5, 6], and three phase 3 trials, AETHERA [7], 
ALCANZA [9-12], and ECHELON-1 [8, 9]. In November 2018, the FDA licensed 
BV in combination with CHP as first-line treatment for sALCL or other CD30-
expressing PTCL, including AITL and PTCL-NOS [13]. Under the Real-Time On-
cology Review Pilot Program, approval occurred less than two weeks following 
the submission of PFS and OS data from the phase 3 ECHELON-2 study [4]. BV 
is not currently indicated as first-line therapy for sALCL or other CD30 expressing 
PTCL in Europe [15]. 
first-line: BV+CHP 
approved for sALCL or 
other CD 30-positive 
PTCL in US; currently 
not indicated in Europe 
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ECHELON-2, a randomised, double-blind, placebo-controlled, phase 3 trial com-
pared the efficacy and safety of BV+CHP versus CHOP in 452 patients with pre-
viously untreated CD30-positive PTCL [4, 35]. At a median follow-up of 42.1 
months, the median OS was not reached for either group. BV+CHP conferred 
longer PFS than CHOP (PFS at 36.2 months: 48.2 months versus 20.8 months), 
reducing the risk of death or progression by 29%. The 3-year PFS was 57.1% for 
BV+CHP versus 44.4% for CHOP. BICR-assessed PFS for sALCL patients was 
consistent with results of the primary analysis (55.7 months for BV+CHP versus 
54.2 months for CHP). Greater OR and CR rates were reported in BV+CHP pa-
tients compared with CHOP (ORR: 83% versus 72%; CRR: 68% versus 56%). 
Durable OR was achieved at all levels of CD30 expression among BV+CHP recip-
ients, including those with 10% CD30 expression. No clinically meaningful differ-
ences in generic or disease-specific QoL scores were observed between groups.  
Commonly reported AEs occurring in 20% of patients in the BV+CHP group in-
cluded nausea, peripheral sensory neuropathy, neutropenia, constipation, alopecia, 
pyrexia, vomiting, fatigue, and anaemia. Grade 3 AEs and SAEs occurred in 66% 
and 38% of BV+CHP patients; and 3% died due to AEs. The most commonly re-
ported grade 3 AEs in BV+CHP recipients were neuropathy (52%), neutropenia 
(38% versus 13% for those with G-CSF primary prophylaxis) and infections 
(19%). Peripheral neuropathy and infections lead to dose delay or reduction in 25% 
and 9% of BV+CHP patients, respectively.  
Results of the ECHELON-2 trial hold some limitations. To ensure the secondary 
endpoint of PFS in sALCL could be appropriately assessed, the trial was designed 
to enrol 75% of patients with sALCL, so approximately 70% of the ITT population 
was comprised of sALCL. The study is limited in that it was not powered to com-
pare efficacy between individual histological subtypes and small subgroup sizes 
preclude definitively determining the treatment effect in non-systematic ALCL. 
HRs for PFS and OS for PTCL-NOS patients were <1, while those for AITL pa-
tients were 1.4 and 0.87, respectively, with wide confidence intervals. Further stud-
ies involving a larger number of AITL or non-sALCL patients are needed to in-
crease the precision by which benefits can be assessed. However, the PFS and OS 
benefits conferred by BV+CHP over CHOP were generally consistent across his-
tological subtypes with overlapping confidence intervals.  
Generalizability of the results may be limited in that while most study participants 
had sALCL, good performance status (ECOG 0–2, an IPI2, and a median age of 
58 years, PTCL-NOS accounts for most PTCL, represents a heterogeneous group, 
and the median age at diagnosis is 60 years [26]. Older patients may experience 
AEs of greater frequency and severity. Among the 31% of BV+CHP study partic-
ipants 65 years of age, 74% experienced an AE of grade 3 severity, 49% expe-
rienced a SAE, and 29% had febrile neutropenia. Neutropenia rates may be under-
estimated as laboratory data were only captured at the start of each cycle. The im-
pact of G-CSF may be limited by incomplete data on cytopenias and by the small 
number of patients that received primary prophylaxis [13]. While there is no gen-
eral consensus regarding optimal treatment for PTCL, a more intensive CHEOP 
regimen may have been a suitable comparator for patients 60 years of age as 
CHOP is typically recommended for patients >60 years of age or less medically 
fit.  
ECHELON-2: BV+CHP 
versus CHOP in 
previously untreated 
CD30-positive PTCL 
 
PFS: BV increased PFS 
by 27.4 months  
 
median OS NR 
 
OR: BV increased OR 
regardless level of CD30 
expression 
 
grade 3 AEs: 
neuropathy, 
neutropenia, and 
infections 
ECHELON-2 limitations: 
insufficient power to 
compare individual 
histological subtypes 
study generalizability 
limited: clinical patients 
most commonly PTCL-
NOS, variable CD30 
expression, older, AEs 
greater frequency and 
severity, may be treated 
with CHEOP  
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ECHELON-2 is a phase 3 trial with few methodological limitations. There was no 
risk of bias in the generation of randomisation sequence or allocation concealment. 
Patients were randomly assigned 1:1 to BV+CHP or CHOP using an interactive 
web-based response system (IWRS). A double-dummy method of blinding was 
used where patients in the BV group received placebo vincristine while those in 
the CHOP group received placebo BV. A pharmacist at each study site prepared 
BV, vincristine and their placebo replacements, and a pharmacy mask was en-
forced. The drugs were dispensed in a double-blind, double-dummy manner where 
patients, treating physicians, and the independent review committee were blinded 
to treatment. Selective outcome reporting is unlikely as the primary endpoint of 
PFS, secondary endpoints of PFS in sALCL patients, CRR, OS, ORR, QoL and 
AEs were reported as specified in the study record for the clinical trial. The risk of 
bias may be increased by industry involvement in funding the study, designing the 
trial, collecting, analysing and interpreting data and supporting manuscript prepa-
ration.  
The clinical efficacy and safety data from ECHELON-2 are consistent with a pre-
viously reported phase 1 trial where BV+CHP was well tolerated and resulted in 
OR, PFS, and OS rates of 100%, 71%, and 88%, respectively, as first-line for 
CD30-positive PTCL [36, 37]. Study populations were generally similar in age, 
stage, histology, and CD30-expression; however, none of the phase 1 patients re-
ceived post-treatment consolidative ASCT. The most common AEs reported in 
both studies included PSN, nausea, fatigue, vomiting, diarrhoea, alopecia and 
dyspnoea. Grade 3 AEs most commonly reported in both studies included febrile 
neutropenia, neutropenia, peripheral neuropathy, infections, anaemia, and pulmo-
nary embolism. While peripheral neuropathy may result in treatment delays or dis-
ruptions, majority resolve with time. Other potential toxicities include PML and 
pulmonary toxicity [3]. 
Several studies are underway to investigate BV as monotherapy or in combination 
with other therapies to treat various stages of CD30-positive PTCL. Recently com-
pleted or ongoing phase 2 or 1 studies are evaluating the safety and effectiveness 
of BV monotherapy for elderly patients with PTCL, combination BV+rituximab in 
lymphomas, the tolerability of CHEP-BV as induction therapy for PTCL, and com-
bination BV+lenalidomide for r/r cutaneous T-cell lymphoma, PTCL or HL. Other 
phase 2 studies are investigating BV monotherapy for r/r CD30-positive or low 
CD30-expressing PTCL, combination bendamustine+BV as first salvage for r/r HL 
or PTCL, and BV following relapse on gemcitabinte or a BV-containing regimen. 
Administered as an intravenous infusion, the recommended dose of 1.8 mg/kg BV 
for a 70 kg person would cost approximately € 9,999.00, every three weeks in com-
bination with CHP. Six cycles of BV+CHP would cost approximately € 59,994.00 
plus the additional cost of CHP. Indicated for previously untreated sALCL or other 
CD30-expressing PTCL and assuming approximately 133 to 200 Austrians may be 
diagnosed with PTCL each year, BV would cost approximately € 7,979,202.00 to 
€ 11,998,800.00 (six cycles of treatment) annually, with additional costs for G-CSF 
prophylaxis, chemotherapy and gene expression profiling.  
Questions remain regarding the patient population who would benefit most from 
BV+CHP therapy, and the relationship between the degree of CD30 expression 
and potential tumour response. The ECHELON-2 trial required 10% CD30 ex-
pression by immunohistochemical analysis; however, the optimal CD30 expres-
sion threshold remains uncertain. Data from ECHELON-2 are based on a popula-
tion comprised 70% of ALCL patients; while ALCL universally expresses CD30, 
expression is variable in other PTCL subtypes. Estimates of CD30 expression 
range from 58–64% in PTCL-NOS, 63–75% in AITL, 0–55% in ATLL, 0–100% 
low risk of bias: 
randomised, double-
blind, double-dummy, 
placebo-controlled 
 
however, industry 
funded 
safety and efficacy 
results consistent with 
previous phase 1 study 
several ongoing studies 
evaluating BV 
monotherapy or in 
combination with other 
agents for CD30-positive 
PTCL at various stages 
€ 9,999.00/cycle, 
additional costs for G-
CSF, chemotherapy and 
genetic profiling 
 
six cycles of BV:  
~ € 59,994.00 
CD30 expression: 
variable in PTCL; 
currently no threshold; 
diagnostic tool needed 
for patient selection 
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in EATL, and 0–25% in hepatosplenic T-cell lymphoma. To better inform patient 
selection for BV+CHP, the FDA has requested that a clinically validated in vitro 
diagnostic for CD30 expression be developed [13].  
Overall, ECHELON-2 is the first phase 3, randomised, double-blind, active com-
parator study to demonstrate that compared with CHOP, BV+CHP increases PFS, 
OR and CR in previously untreated CD30-positive PTCL patients. While the PFS 
benefits were generally consistent across subtypes, the study was not powered to 
compare efficacy between individual histological subtypes and small sample sizes 
preclude definitively determining the treatment effect in non-systematic ALCL. No 
clinically meaningful differences were noted in QoL measures. The development 
of a clinically validated in vitro diagnostic for CD30 expression may ensure the 
appropriate selection of patients most likely to benefit from BV+CHP therapy. Fur-
ther studies are needed to better define the efficacy of BV in non-ALCL histolo-
gies, optimal dosing to enhance disease control while limiting complications, opti-
mal therapeutic sequence, and use as monotherapy versus in combination with im-
mune checkpoint inhibitors or other immunomodulatory agents.  
 
 
 
ECHELON-2: phase 3 
RCT demonstrates PFS 
benefit of BV+CHP over 
CHOP 
 
no difference in QoL 
 
efficacy in non-ALCL 
histologies, optimal 
dosing and therapeutic 
sequence, monotherapy 
versus in combination 
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12 Appendix  
Table 3: Administration and dosing and of BV+CHP or CHOP [3, 4] 
 BV + CHP CHOP 
Admin-
istration 
mode 
BV IV over 30 minutes, approximately 1 hour after CHP [3] Double-blind, double-dummy [4] 
Descrip-
tion of 
packaging 
50 mg white lyophilized powder in a single-dose vial for re-
constitution with 10.5 mL of sterile water for injection USP 
(solution of 5 mg/mL BV); withdraw required volume and 
transfer into IV bag containing 100 mL of 0.9% sodium 
chloride injection, 5% dextrose injection or lactated ringer’s 
injection (final concentration of 0.4-1.8 mg/mL BV) [3]. 
Double-blind, double-dummy; BV, 
vincristine and placebo replacements 
prepared by onsite pharmacist [4] 
Total vol-
ume con-
tained in 
packaging 
for sale 
50 mg of BV powder in individually-boxed single-dose vials 
[3] 
Double-blind, double-dummy; [4] 
Dosing 
Brentuximab vedotin (1.8 mg/kg IV, maximum 180 mg) + 
cyclophosphamide (750 mg/m2 IV) + doxorubicin  (50 mg/m2 
IV) + placebo vincristine IV on day 1 + prednisone (100 mg 
oral) daily on days 1-5 of each 21-day cycle, for 6-8 cycles. 
Previously untreated PTCL patients received G-CSF prior to 
first BV + CHP cycle. Reduce dose to 1.2 mg/kg for patients 
with mild hepatic impairment (Child-Pugh A), grade 2 motor 
neuropathy, or grade 3 sensory neuropathy. Discontinue in 
patients with grade 3 motor neuropathy or PML [3, 35].  
Placebo brentuximab vedotin + cy-
clophosphamide (750 mg/m2 IV) + 
doxorubicin  (50 mg/m2 IV) + vin-
cristine  (1.4 mg/m2, maximum 2 mg 
IV) on day 1 + prednisone (100 mg 
oral), once daily on days 1-5, of each 
21-day cycle, for 6-8 cycles [4]. 
Median 
treatment 
duration 
89% received 6-8 cycles [4]. 81% received 6-8 cycles [4]. 
Contrain-
dications 
Not for use in patients with severe renal (CrCL<30 ml/min) 
or hepatic (Child-Pugh B or C) impairment. BV is contraindi-
cated with concomitant bleomycin due to pulmonary tox-
icity [3]. 
Not for use in patients with severe 
renal (CrCL<30 ml/min) or hepatic 
(Child-Pugh B or C) impairment. BV 
is contraindicated with concomitant 
bleomycin due to pulmonary toxicity 
[3]. 
Drug in-
teractions 
Closely monitor AEs if given concomitantly with strong 
CYP3A4 inhibitors. Co-administration with ketoconazole in-
creased exposure to MMAE increasing risk of AE [3].  
Double-blind, double-dummy; [4] 
Abbreviations: AE = adverse event; BV = brentuximab vedotin; CrCL = creatinine clearance; CHOP = cyclophosphamide, doxo-
rubicin, vincristine, and prednisone; CHP = CHOP without vincristine; G-CSF = granulocyte colony-stimulating factor; MMAE = 
monomethyl auristatin E; PML = progressive multifocal leukoencephalopathy; USP = United States Pharmacopeia 
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Table 4: Characteristics of the ECHELON-2 trial [4] 
Title: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-
blind, randomised, phase 3 trial [4, 35] 
Study identifier NCT01777152, EudraCT 2012-002751-42, SGN35-014, ECHELON-2 
Design International (17 countries), multicentre (132 sites), double-blind, double-dummy, randomised, pla-
cebo-controlled, interventional phase III 
Duration of main phase: Patients received 21-day cycles of BV+CHP or CHOP for 6 or 
8 cycles at the investigator’s discretion. The data cut-off for 
primary analysis was August 15, 2018.  
Duration of enrolment: January 24, 2013 – Nov 7, 2016, 601 patients were enrolled.  
Duration of extension phase: CT scans were required at 9, 12, 15, 18, 21, and 24 months 
after initiating study treatment, and every 6 months there-
after until progression, death, or analysis of the primary 
endpoint up to 7 years post-treatment.  
Hypothesis 
Superiority 
The study was designed to compare the efficacy and safety of brentuximab vedotin in combination 
with CHP (A+CHP) versus standard CHOP for the treatment of untreated patients with CD30-posi-
tive PTCL.  
Funding Seattle Genetics, Inc. 
Treatments groups 
 
BV+CHOP (6-8 cycles) 
(n = 226 efficacy; n = 223 safety) 
Brentuximab vedotin: 1.8 mg/kg IV (day 1) 
Cyclophosphamide: 750 mg/m2 IV (day 1) 
Doxorubicin: 50 mg/m2 IV (day 1) 
Placebo vincristine IV (day 1) 
Prednisone: 100 mg orally on days 1-5 of each 3-week cycle  
CHOP (6-8 cycles) 
(n = 226 efficacy; n = 226 safety) 
Placebo brentuximab vedotin (day 1) 
Cyclophosphamide: 750 mg/m2 IV (day 1) 
Doxorubicin: 50 mg/m2 IV (day 1) 
Vincristine: 1.4 mg/m2 (maximum 2 mg) IV 
Prednisone: 100 mg orally on days 1-5 of each 3-week cycle 
 
Notes 
Consolidative stem cell transplantation or radiotherapy af-
ter treatment was permitted at the investigator’s discre-
tion 
Endpoints and definitions 
 
Progression-free survival  
Primary endpoint 
PFS Time from randomisation until progression, subsequent 
anticancer chemotherapy, death or study closure, for up to 
5 years post-treatment, as assessed by BICR.  
Progression-free survival  
Secondary endpoint 
PFS 
Time from randomisation until progression, subsequent 
anticancer chemotherapy, death or study closure, for up to 
5 years post-treatment, as assessed by BICR, in patients 
with centrally confirmed sALCL 
Complete remission rate 
Secondary endpoint 
 
CRR 
 
At end of treatment, as assessed by BICR. 
Overall survival 
Secondary endpoint OS 
Time from randomisation until death or study closure, up 
to 7 years post-treatment 
Objective response rate 
Secondary endpoint 
ORR Proportion of patients who achieved an objective re-
sponse, according to BICR, at the end of treatment.  
Adverse events 
Secondary endpoint AEs 
AEs graded by CTCAE version 4.03, up to one month fol-
lowing last dose.  
Efficacy by CD30 expres-
sion 
Exploratory endpoint 
_ 
The relationship between CD30 expression and overall re-
sponse and DOR  
Database lock Last update posted October 11, 2018 
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Title: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-
blind, randomised, phase 3 trial [4, 35] 
Study identifier NCT01777152, EudraCT 2012-002751-42, SGN35-014, ECHELON-2 
Analysis description Primary Analysis 
ITT: efficacy analyses included all patients randomised unless otherwise specified. Safety analyses 
included patients who received any amount of BV or any component of CHOP.  
BICR-assessed PFS, CRR, OS, and ORR were tested statistically using a two-sided  of 0.5, CIs at 
two-sided 95% level, results favouring treatment with p<0.05 are significant at the one-sided 0.025 
level. Missing data were not imputed; subjects with missing values of a variable other than PFS or 
OS were excluded from the analysis of that endpoint.  
Primary efficacy analysis was a stratified log-rank test (by randomisation stratification factors) to 
compare the difference in BICR-assessed PFS between treatment groups. HR was estimated based 
on the stratified Cox regression model. PFS was also summarised using Kaplan-Meier. Similar meth-
ods were used for secondary efficacy endpoints of PFS in patients with sALCL and OS. PFS and OS 
median follow-up was calculated using the reverse Kaplan-Meier methods. The proportion of pa-
tients with an objective response and complete remission between groups was tested using the 
Cochran-Mantel-Haenszel test, stratified by the randomisation stratification factors.  
Assuming a median PFS of 23.9 m for the BV+CHP group and 16.5 m for the CHOP group, an esti-
mated 238 PFS events provided an 80% power to detect a HR for disease progression or death due 
to any cause of 0.6895 at a one-sided significance level of 0.025; planned enrolment of 450 pa-
tients, targeting 75% (±5%) of patients with sALCL to ensure the secondary endpoint could be as-
sessed.  
Analysis population   
Inclusion 
 Adults with untreated CD30-positive (≥ 10% of cells by 
local review) mature T-cell lymphomas according to 
the WHO 2008 classification  
 Histologies included ALK-positive sALCL with IPI score 
≥ 2, ALK-negative sALCL, PTCL-NOS, AITL, ATLL, EATL, 
and hepatosplenic T-cell lymphoma 
 FDG-avid disease by PET, measurable disease of at 
least 1.5 cm by CT 
 ECOG performance status ≤ 2 
 ALT and AST ≤ 3X ULN or ≤ 5X ULN for subjects with 
hepatic involvement, serum creatinine ≤ 2X ULN, ANC 
≥ 1000/µL, or platelet count ≥ 50,000/µL 
 
Exclusion 
 History of another primary invasive cancer, hemato-
logic malignancy, or myelodysplastic syndrome that 
has not been in remission for at least 3 years 
 Current diagnosis of primary cutaneous CD30-positive 
T-cell lymphoproliferative disorders and lymphomas or 
mycosis fungoides 
 History of PML 
 Cerebral/meningeal disease related to the underlying 
malignancy 
 Prior treatment with brentuximab vedotin 
 Baseline peripheral neuropathy ≥ 2 per NCI-CTCAE 
4.03 or demyelinating Charcot-Marie-Tooth syndrome 
 Left ventricular ejection fraction ≤ 45%, symptomatic 
cardiac disease or myocardial infarction within the 
past 6 months, or previous treatment with complete 
cumulative doses of anthracyclines 
 Active grade 3≥  viral, bacterial or fungal infection 
within two weeks prior to the first dose of study treat-
ment; HIV, or hepatitis B or C 
 
Characteristics 
 
 
B+CHP 
(n = 226) 
 
CHOP 
(n = 226) 
 
Total 
(n = 452) 
Age, years 
  Median (IQR) 
  ≥ 65, n (%) 
 
58.0 (45-67) 
69 (31) 
 
58.0 (44-67) 
70 (31) 
 
58.0 (44-67) 
70 (31) 
Male, n (%) 133 (59) 151 (67) 142 (63) 
Median time from diagnosis 
(months) 0.8 0.9 0.9 
Race, n (%) 
  Asian 
  African American 
  Caucasian 
  Hawaiian or Pacific Islander 
  Other or unknown 
 
45 (20) 
12 (5) 
139 (62) 
1 (0) 
29 (13) 
 
54 (24) 
6 (3) 
142 (63) 
0 (0) 
24 (11) 
 
50 (22) 
9 (4) 
141 (63) 
1 (0) 
27 (12) 
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Title: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-
blind, randomised, phase 3 trial [4, 35] 
Study identifier NCT01777152, EudraCT 2012-002751-42, SGN35-014, ECHELON-2 
ECOG performance-status, n (%) 
  0 
  1 
  2 
 
84 (37) 
90 (40) 
51 (23) 
 
93 (41) 
86 (38) 
47 (21) 
 
89 (39) 
88 (39) 
49 (22) 
Diagnosis, n (%) 
  sALCL 
  ALK-positive 
  ALK-negative 
  PTCL-NOS 
  AITL 
  ATLL 
  EATL 
 
162 (72) 
49 (22) 
113 (50) 
29 (13) 
30 (13) 
4 (2) 
1 (0) 
 
154 (68) 
49 (22) 
105 (46) 
43 (19) 
24 (11) 
3 (1) 
2 (1) 
 
158 (70) 
49 (22) 
109 (48) 
36 (16) 
27 (12) 
4 (2) 
2 (1) 
Disease stage at diagnosis, n (%) 
  1 
  2 
  3 
  4 
 
12 (5) 
30 (13) 
57 (25) 
127 (56) 
 
9 (4) 
37 (16) 
67 (30) 
113 (50) 
 
11 (5) 
34 (15) 
62 (28) 
120 (53) 
IPI score, n (%) 
  0 
  1 
  2 
  3 
  4 
  5 
 
8 (4) 
45 (20) 
74 (33) 
66 (29) 
29 (13) 
4 (2) 
 
16 (7) 
32 (14) 
78 (35) 
66 (29) 
25 (11) 
9 (4) 
 
12 (6) 
39 (17) 
76 (34) 
66 (29) 
27 (12) 
7 (3) 
% CD30 expression, per BICR 
  Mean (SD) 
  Range 
 
81 (28) 
0–100 
 
78 (31) 
0–100 
 
80 (30) 
0-100 
% CD30 expression, ALCL, per BICR 
  Mean (SD) 
  Range 
 
95 (11) 
0–100 
 
93 (14) 
0–100 
 
94 (13) 
0-100 
% CD30 expression, non-ALCL, BICR 
  Mean (SD) 
  Range 
 
47 (30) 
5–100 
 
46 (31) 
0–100 
 
47 (31) 
0-100 
Applicability of evidence 
Population 
ECHELON-2 was conducted in patients with newly diagnosed, CD30-positive PTCL with good perfor-
mance status (ECOG 0–1), and an IPI score of 3. Generalizability of  the results may be limited in 
that most study participants had sALCL and a median of 58 years while PTCL-NOS accounts for most 
PTCL, represents a heterogeneous group, and the median age at PTCL diagnosis is 60 years. Older 
patients may experience AEs of greater severity; of the 31% of BV+CHP patients 65 years of age, 
74% experienced an AE of 3 severity, 33% had a SAE and 29% had febrile neutropenia.  
Intervention 
The dosage and administration of BV used in ECHELON-2 is consistent with that recommended for 
previously untreated PTCL. Dose reductions were allowed for patients with mild hepatic impairment, 
grade 2 motor neuropathy or grade 3 sensory neuropathy. Consolidative therapy was permitted.  
Comparators 
PTCL is a heterogeneous group of mature T-cell lymphomas for which there is no general consensus 
regarding the optimal treatment regimen. Newly diagnosed PTCL patients are typically treated with 
anthracycline-based chemotherapy regimens. CHOP is often recommended for patients >60 years of 
age or less medically fit, whereas CHEOP may be recommended for patients 60 years of age. While 
study participants were a median of 58 years of age, CHOP was used as the comparator.  
Outcomes 
Neutropenia rates may be underestimated because laboratory data were captured only at the start 
of each cycle. Evaluation of the impact of G-CSF was limited by the incomplete data on cytopenias, 
and by the small number of patients who received primary prophylaxis.  
Setting 
ECHELON-2 is a multination study conducted in 132 sites across Australia, Canada, Czech Republic, 
Denmark, France, Germany, Hungary, Israel, Italy, Japan, Poland, Republic of Korea, Romania, Spain, 
Taiwan, United Kingdom, and United States.   
Abbreviations: AITL = angioimmunoblastic T-cell lymphoma; ALK = anaplastic lymphoma kinase; ALT = alanine aminotransferase; ANC = 
absolute neutrophil count; AST = aspartate aminotransferase; AITL = angioimmunoblastic T-cell lymphoma; ATLL = adult T-cell 
leukaemia/lymphoma; BICR = blinded independent central review; BV+CHP = brentuximab vedotin, cyclophosphamide, doxorubicin, and 
prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; CHP = CHOP without vincristine; CI = confidence interval; 
CRR = complete remission rate; CT = computed tomography; DOR = duration of response; EATL = enteropathy-associated T-0cell lymphoma; 
ECOG = Eastern Cooperative Oncology Group; FDG = fluorodeoxyglucose; HIV = human immunodeficiency virus; HR = hazard ratio; IPI = 
International Prognostic Index; IQR = interquartile range; ITT: intent-to-treat; NCI-CTCAE = National Cancer Institute-Common Terminology 
Criteria for Adverse Events; ORR = overall response rate; OS = overall survival; PET = positron emission tomography; PML = progressive 
multifocal leukoencephalopathy; PTCL-NOS = peripheral T-cell lymphoma not otherwise specified; sALCL = systemic anaplastic large cell 
lymphoma; ULN = upper limit of normal; WHO = World Health Organization 
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Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [38] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: randomised 1.1 to BV+CHP or CHOP using an IWRS 
that assigned a unique patient randomisation number and did not specify actual treatment assignment. 
Randomisation was stratified by histological subtype according to pathology assessment (ALK-positive 
sALCL versus other histologies) and IPI score (0-1 versus 2-3 versus 4-5).  
yes 
Adequate allocation concealment: centralised randomisation and allocation; blinded study medication 
was administered based on assignment from the IWRS. BV and vincristine were dispensed in a double-
blinded, double-dummy manner. The pharmacist at each study site prepared BV, vincristine and their 
placebo replacements and a pharmacy mask was enforced.  
yes 
Blinding: 
Patient: centralised randomisation and allocation; BV and vincristine were dispensed 
in a double-blind, double-dummy manner and patients were masked to treatment 
assignment. 
yes 
Treating physician: centralised randomisation and allocation; BV and vincristine 
were dispensed in a double-blind, double-dummy manner and investigators were 
masked to treatment assignment. 
yes 
Outcome assessor: centralised randomisation and allocation; BICR were masked to 
treatment assignment, and assessed efficacy and safety at interim analysis. 
yes 
Selective outcome reporting unlikely: primary endpoint of PFS, secondary endpoints of PFS in patients 
with sALCL, CRR, OS, ORR and AEs were reported as per protocol.  
yes 
No other aspects which increase the risk of bias: industry funded the study, designed the trial, collected, 
analysed and interpreted the data, and supported manuscript preparation. 
yes 
Risk of bias – study level low-risk 
Abbreviations: BICR = blinded independent review committee; BV+CHP = brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone; 
CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; CRR = complete remission rate; IPI = International Prognostic Index; IWRS 
= interactive web response system; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; sALCL = systemic ana-
plastic large cell lymphoma 
 
